Brief: Gensight Biologics's GS010/Lumevoq® Phase II Study To Start In Jan 2026

Gensight Biologics SA

02/12/2025 18:15

Dec 2 (Reuters) - Gensight Biologics SA SIGHT.PA:

GENSIGHT BIOLOGICS ANNOUNCES REGULATORY APPROVAL FOR GS010/LUMEVOQ® REVISE DOSE-RANGING STUDY IN FRANCE

GENSIGHT BIOLOGICS SA - PHASE II STUDY EXPECTED TO START IN JANUARY 2026

GENSIGHT BIOLOGICS : PURSUING OPPORTUNITIES TO OUT-LICENSE GS010 IN MARKETS OUTSIDE USA & EUROPE, WHILE EXPLORING PAID EARLY ACCESS PROGRAMS WORLDWIDE

Source text: ID:nBwbTVxRGa

Further company coverage: SIGHT.PA

 ((((Reuters.Briefs@thomsonreuters.com));))